%0 Journal Article %1 Cai:2018:J-Clin-Pathol:29550762 %A Cai, H Q %A Wang, P F %A Zhang, H P %A Cheng, Z J %A Li, S W %A He, J %A Zhang, Y %A Hao, J J %A Wang, M R %A Yan, C X %A Wan, J H %D 2018 %J J Clin Pathol %K ATRX IDH astrocytoma biomarkers cancer-research fulltext %R 10.1136/jclinpath-2018-205000 %T Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1R132H mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss %U https://www.ncbi.nlm.nih.gov/pubmed/29550762 %X To identify biomarkers for accurate classification of glioma.We evaluated the heat shock protein 27 (Hsp27), phosphorylated Hsp27 (p-Hsp27), ATRX and IDH1R132Hproteins using immunohistochemistry in 421 glioma tissues. The χ2 test was used to assess the relationship between molecular alterations and clinico-pathological parameters. Kaplan-Meier survival curves were constructed, and differences were detected by the log-rank test.We found that Hsp27 and p-Hsp27 were mainly expressed in aggressive astrocytic gliomas. However, neither Hsp27 nor p-Hsp27 expression was related to survival time for any grade of glioma. Interestingly, p-Hsp27 was mutually exclusive with ATRX loss (ATRX-) and the IDH1R132H mutation, except for one case of anaplastic astrocytoma. We classified glioblastomas (GBMs) into three subtypes: ATRX-/IDH1R132H, high p-Hsp27 expression (p-Hsp27+) and none of these three markers. ATRX-/IDH1R132Hshowed the longest median survival (19.6 months). The prognostic difference between p-Hsp27+ and none of these three markers was significant (15.0 vs 13.1 months, P=0.045). Moreover, p-Hsp27+ predicted better sensitivity for standard therapy among GBMs without the IDH1 mutation and ATRX loss (26.3 vs 15.5 months, P=0.008).p-Hsp27 is a novel biomarker of glioma and might have important clinical value for further classification of patients with wild-type IDH1 and normal ATRX expression, for evaluating prognosis and for guidance for adjuvant therapy.

@article{Cai:2018:J-Clin-Pathol:29550762, abstract = {To identify biomarkers for accurate classification of glioma.We evaluated the heat shock protein 27 (Hsp27), phosphorylated Hsp27 (p-Hsp27), ATRX and IDH1R132Hproteins using immunohistochemistry in 421 glioma tissues. The χ2 test was used to assess the relationship between molecular alterations and clinico-pathological parameters. Kaplan-Meier survival curves were constructed, and differences were detected by the log-rank test.We found that Hsp27 and p-Hsp27 were mainly expressed in aggressive astrocytic gliomas. However, neither Hsp27 nor p-Hsp27 expression was related to survival time for any grade of glioma. Interestingly, p-Hsp27 was mutually exclusive with ATRX loss (ATRX-) and the IDH1R132H mutation, except for one case of anaplastic astrocytoma. We classified glioblastomas (GBMs) into three subtypes: ATRX-/IDH1R132H, high p-Hsp27 expression (p-Hsp27+) and none of these three markers. ATRX-/IDH1R132Hshowed the longest median survival (19.6 months). The prognostic difference between p-Hsp27+ and none of these three markers was significant (15.0 vs 13.1 months, P=0.045). Moreover, p-Hsp27+ predicted better sensitivity for standard therapy among GBMs without the IDH1 mutation and ATRX loss (26.3 vs 15.5 months, P=0.008).p-Hsp27 is a novel biomarker of glioma and might have important clinical value for further classification of patients with wild-type IDH1 and normal ATRX expression, for evaluating prognosis and for guidance for adjuvant therapy.}, added-at = {2018-05-18T19:28:22.000+0200}, author = {Cai, H Q and Wang, P F and Zhang, H P and Cheng, Z J and Li, S W and He, J and Zhang, Y and Hao, J J and Wang, M R and Yan, C X and Wan, J H}, biburl = {https://www.bibsonomy.org/bibtex/2e603d204b9ca9f9aacd38ad734b579bd/marcsaric}, description = {Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1R132H mutation and may predict better prognosis among glioblastomas without t... - PubMed - NCBI}, doi = {10.1136/jclinpath-2018-205000}, interhash = {9cd1e0b3b7ee51f941cf6ca3a4ca8f49}, intrahash = {e603d204b9ca9f9aacd38ad734b579bd}, journal = {J Clin Pathol}, keywords = {ATRX IDH astrocytoma biomarkers cancer-research fulltext}, month = mar, pmid = {29550762}, timestamp = {2018-05-18T19:28:37.000+0200}, title = {Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1R132H mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss}, url = {https://www.ncbi.nlm.nih.gov/pubmed/29550762}, year = 2018 }